Core Viewpoint - Molina Healthcare Inc. experienced a significant stock decline following a fourth-quarter earnings miss, reporting an unexpected adjusted loss of $2.75 per share compared to Wall Street's expectation of a profit of $0.34, leading to a more than 30% drop in stock price in a single session [2][4]. Financial Performance - The fourth-quarter loss was primarily due to $2.00 per share in unfavorable retroactive revenue adjustments in California and rising medical costs in Medicare and Marketplace segments [5]. - The stock is down 24.16% year-to-date, with a 49.60% decline over the past year, while the S&P 500 has only decreased by 0.33% during the same period [6]. Technical Indicators - Following the earnings report, Molina's stock momentum score fell from 14.04 to 5.72, indicating a significant deterioration in technical indicators [3]. - The stock maintains a weaker price trend across long, short, and medium terms, despite having a strong value ranking according to Benzinga's Edge Stock Rankings [3]. Investor Sentiment - Michael Burry, known for his "Big Short" investment strategy, has reaffirmed a contrarian position in Molina, despite facing a 27% loss on his estimated purchase price, arguing that the market's reaction is excessively negative [4]. Future Outlook - CEO Joseph Zubretsky has described 2026 as a "trough year" for margins, projecting an adjusted EPS of at least $5.00, which is significantly lower than previous forecasts, as the company transitions away from traditional Medicare Advantage products [5].

Financial Performance - Molina Healthcare reported premium revenue of $43,052 million for the year ended December 31, 2025, an increase of 11.7% from $38,627 million in 2024[18]. - Total revenue for Molina Healthcare reached $45,426 million in 2025, up from $40,650 million in 2024, reflecting a growth of 11.7%[18]. - Net income decreased to $472 million in 2025 from $1,179 million in 2024, resulting in a net income per diluted share of $8.92 compared to $20.42 in the previous year[18]. - Medicaid premium revenue constituted 75% of the company's consolidated premium revenue for the year ended December 31, 2025[148]. - The company's overall medical care ratio was 91.7% for the year ended December 31, 2025; a one percentage point increase would have reduced net income per diluted share from $8.92 to $2.72, a difference of $6.20[145]. Membership and Enrollment - Molina Healthcare's total membership as of December 31, 2025, was approximately 5.5 million, a slight decrease from 5.5 million in 2024, with Medicaid membership declining to 4,568,000[21]. - The company anticipates a 15% to 20% reduction in Medicaid Expansion membership due to the One Big Beautiful Bill Act (OBBBA) over the next two to three years[27]. - Expected Medicare enrollment decrease of approximately 12% in 2026, totaling 230,000 members, including 80,000 Medicare Advantage-Part D members[57]. - Marketplace enrollment expected to decrease to approximately 220,000 members by the end of 2026, representing an estimated premium revenue decrease of approximately 50%[70]. - The company estimates a reduction in Medicaid enrollment of 15% to 20% by 2029, affecting approximately 1.2 million members in its Medicaid Expansion population[77]. Strategic Initiatives - Molina Healthcare's strategic plan includes a long-term premium revenue growth target of 11% to 13%, aiming to surpass $50 billion in premium revenue by 2027[33]. - The company completed the acquisition of ConnectiCare for $350 million, which is expected to contribute approximately $9 billion in incremental annual premium revenue[37][28]. - Company is focused on operational restructuring and enrollment alignment to support long-term growth opportunities in the dual eligible market[56]. - The company’s growth strategy includes targeted acquisitions, but successful integration and realization of anticipated benefits are complex and uncertain[160]. Regulatory and Compliance - The company is subject to stringent regulatory capital requirements that limit its ability to pay dividends[129]. - The company has implemented HIPAA compliance programs to ensure adherence to privacy and security regulations, which may incur additional costs[121]. - The company is subject to extensive fraud and abuse laws, which may result in significant fines, civil penalties, or other sanctions[198]. - The company is subject to various federal and state data privacy laws, including HIPAA and the CCPA, which impose significant compliance obligations[210]. Market Competition - The company faces significant competition in the Medicaid market from organizations like Centene Corporation and UnitedHealth Group Inc., impacting contract retention and member acquisition[114]. - The Medicare market is highly competitive, with major competitors including CVS Health Corporation and Humana, influencing pricing and bid strategies[116]. Operational Risks - The company is exposed to cybersecurity risks that could result in operational impacts and significant legal liabilities[154]. - The company may face cyberattacks and incidents that could adversely impact operations and financial results, although no material incidents have occurred to date[158]. - The company is vulnerable to operational disruptions if third-party vendors fail to perform adequately[182]. - The company faces risks related to the accuracy and completeness of encounter data, which is critical for compliance and premium rate determination[184]. Healthcare Costs and Pricing - The medical care costs are influenced by various factors, including hospital costs, pharmacy costs, and changes in healthcare regulations[149]. - The introduction of new high-cost specialty drugs and sudden cost spikes for existing drugs could jeopardize the actuarial soundness of the company's capitation rates[214]. - The unpredictable nature of pharmaceutical costs, including geographic variations and changes in discounts, may materially affect the company's financial results[213]. Employee Engagement and Benefits - Employee engagement survey results indicate continued high levels of engagement that exceed industry benchmarks[132]. - The company offers a comprehensive suite of benefits, including 401(k) matching contributions and paid parental leave, to attract and retain talent[138].

Core Viewpoint - Molina Healthcare is facing legal scrutiny while maintaining a robust market presence, with a new price target suggesting potential growth despite challenges [2][3][5]. Group 1: Company Overview - Molina Healthcare (NYSE: MOH) provides managed health care services under Medicaid and Medicare programs, targeting low-income families and individuals across several U.S. states [1]. - The company competes with major players like UnitedHealth Group and Centene Corporation [1]. Group 2: Stock Performance - As of the latest data, Molina's stock is priced at $127.53, reflecting a decrease of 3.18% or $4.19 [4][6]. - The stock has shown significant volatility, with a daily trading range between $123.73 and $135.94, and a yearly high of $359.97 and low of $123.73 [4]. Group 3: Market Capitalization and Trading Activity - Molina Healthcare has a market capitalization of approximately $6.56 billion, indicating its substantial size and market presence [5]. - The trading volume for the day is reported at 4,660,173 shares on the NYSE, suggesting active investor interest despite ongoing legal challenges [5]. Group 4: Analyst Insights - Andrew Mok from Barclays has set a new price target for Molina Healthcare at $133, indicating a potential increase of 4.29% from the current stock price [2][6]. Group 5: Legal Issues - Grabar Law Office is investigating potential breaches of fiduciary duties by Molina's officers and directors, linked to a securities fraud class action complaint regarding undisclosed adverse facts about its "medical cost trend assumptions" [3][6].

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Molina Healthcare, Inc. regarding potential breaches of fiduciary duties by certain officers and directors of the company [1]. Group 1: Investigation Details - The investigation is focused on whether Molina Healthcare's officers and directors failed to disclose material adverse facts related to the company's financial health, specifically concerning "medical cost trend assumptions" and a "dislocation between premium rates and medical cost" [3]. - Allegations include that Molina Healthcare's near-term growth relied on a lack of utilization of various health services, which could lead to a significant reduction in the company's financial guidance for fiscal year 2025 [3]. Group 2: Shareholder Actions - Shareholders who purchased Molina Healthcare shares prior to February 5, 2025, and still hold them can seek corporate reforms, the return of funds to the company, and a court-approved incentive award at no cost [2][4]. - Interested shareholders are encouraged to contact Grabar Law Office for more information on how to proceed with their claims [2][4]. Group 3: Law Firm Background - Grabar Law Office is recognized for its extensive experience in complex commercial litigation, particularly in securities class actions and individual shareholder litigation under federal and state laws [5]. - The firm has a strong reputation, with its lawyers rated for high levels of professional excellence and ethical standing [5].

Core Insights - Molina Healthcare (MOH) is a dedicated health insurance company facing margin pressure due to claims inflation [1] Company Performance - Molina reported its Q4 2025 results, indicating ongoing challenges in maintaining profitability amidst rising claims costs [1]

Core Viewpoint - Molina Healthcare is facing margin pressure due to claims inflation, which is a common challenge in the health insurance sector [1]. Company Summary - Molina Healthcare (MOH) is identified as a pure play health insurance company [1]. - The company recently released its Q4 2025 results, indicating ongoing struggles within the industry [1]. Industry Summary - The health insurance sector is experiencing significant margin pressure attributed to rising claims inflation, affecting multiple players in the market [1].

And right now we are 2 minutes away from the end of the trading day. Romaine Bostick here with Katie Greifeld taking you through to that closing bell with a global simulcast Carol Massar and Tim Stenovec, join us right now. Welcome to our audiences across bloomberg television, Bloomberg radio.Our partnership with you here on a huge turnaround in financial markets with all of the major indices basically up at a minimum by 2% on the day. Yeah, I've been thinking about you because I'm looking at the Russell 20 ...

Core Insights - Molina Healthcare, Inc. reported a fourth-quarter 2025 adjusted loss of $2.75 per share, significantly missing the Zacks Consensus Estimate of an adjusted EPS of 43 cents, compared to an EPS of $5.05 in the prior-year quarter [1][9] - Revenues for the quarter reached $11.4 billion, reflecting an 8.3% year-over-year increase and surpassing the consensus estimate by 5.3% [1][5] Financial Performance - For the full year 2025, Molina reported total revenues of $45.4 billion, up from $40.7 billion in 2024, exceeding the consensus estimate of $44.8 billion [5] - Adjusted EPS for 2025 declined to $11.03 from $22.65 in 2024 but still beat the consensus estimate of $10.65 [5] - Adjusted net income fell to $584 million from $1.3 billion a year ago [5] Operational Highlights - Premium revenues in Q4 totaled $10.7 billion, a 7.3% year-over-year increase, exceeding both the Zacks Consensus Estimate and internal estimates [6] - Total membership as of December 31, 2025, declined by 0.8% year over year to approximately 5.49 million, missing the Zacks Consensus Estimate of 5.52 million [6] - The medical care ratio (MCR) increased by 440 basis points year over year to 94.6%, exceeding both the consensus estimate and internal estimates [8] Expense and Income Analysis - Investment income decreased by 11.7% year over year to $98 million, below the consensus estimate of $100.1 million [7] - Total operating expenses rose by 14% year over year to $11.5 billion, exceeding internal estimates, primarily due to higher medical care costs and increased general and administrative expenses [7][8] - Interest expense grew by 52.9% year over year to $52 million [8] Future Guidance - For 2026, management expects premium revenues to decline by 2% year over year to $42.2 billion, with adjusted earnings projected to be at least $5.00 per share [12] - Adjusted net income is anticipated to be $256 million, with total membership estimated to decrease to 5.1 million by the end of 2026 [13]

Group 1 - The storage sector showed strength with SanDisk rising by 6.1%, Western Digital increasing by 3.8%, and Seagate Technology up by 4.5% [1] - Reddit's stock increased by 6.6% as the company announced a plan to repurchase $1 billion in shares [1] Group 2 - Amazon's stock fell by 8.8% due to concerns over a $200 billion capital expenditure plan [1] - Molina Healthcare experienced a significant drop of 30% after reporting an adjusted loss of $2.75 per share [1]

Financial Data and Key Metrics Changes - The company reported an adjusted loss per share of $2.75 on premium revenue of $10.7 billion for Q4 2025, which was below expectations due to strong trend pressure in Medicare and Marketplace, along with retroactive items in Medicaid totaling $2 per share [6][19] - For the full year 2025, premium revenue was $43 billion, reflecting an 11% year-over-year growth, while adjusted earnings per share were $11.03, with a pretax margin of 1.6% [7][8] - The Medicaid Medical Care Ratio (MCR) for Q4 was 93.5%, and for the full year, it was 91.8% with a pretax margin of 2.8% [9][21] Business Line Data and Key Metrics Changes - In Medicaid, the MCR for Q4 was 93.5%, impacted by retroactive premium rate actions, while the adjusted MCR was 92.3% with a pretax margin of 2% [7][20] - The Medicare MCR for Q4 was 97.5%, with elevated utilization affecting margins, while the full year MCR was 92.4% [21] - The Marketplace MCR was 99% for Q4, influenced by high utilization and prior period claim settlements, with a full year MCR of 90.6% [22] Market Data and Key Metrics Changes - The company secured a historic RFP win in Florida, expected to yield $6 billion in annual run rate premium, complementing previous contract wins in Wisconsin, Georgia, and Texas, contributing over $9 billion in Medicaid premium [11] - The company anticipates 2026 premium revenue of approximately $42 billion, slightly lower than 2025, with growth from the Florida CMS contract offset by a planned reduction in the Marketplace segment [12][29] Company Strategy and Development Direction - The company aims to focus on dual-eligible members in Medicare, planning to exit the traditional MAPD product for 2027 [14] - The acquisition pipeline remains active, with the company looking to capitalize on opportunities in a challenging operating environment [12] - The company projects a low single-digit margin in Medicaid for 2026, indicating confidence in future rate restoration and earnings potential [17] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment in the 2025 results but remains confident in the long-term outlook, expecting Medicaid rates and medical cost trends to reach equilibrium [10][17] - The company believes the 2026 forecast for Medicaid represents a trough for managed Medicaid margins, with potential for recovery in subsequent years [17] - Management highlighted that every 100 basis points on the Medicaid MCR is worth nearly $5 per share, indicating significant upside potential [17] Other Important Information - The company reported a capital foundation that remains strong, with a parent company cash balance of approximately $223 million at year-end [23] - The adjusted G&A ratio for Q4 was 6.9%, reflecting disciplined cost management [22] Q&A Session Summary Question: Variance in Medicaid margins across states and potential exit considerations - Management indicated that rates are generally underfunded across the portfolio, with no current plans for exits from any states [36] Question: Adjustments to benefit design in Medicaid - Management noted some sporadic adjustments but no wholesale shifts in benefit design across states [42][48] Question: Membership attrition assumptions for 2026 - Management expects a 2% membership attrition, attributing the decline to program integrity and tightening enrollment processes [50][52] Question: Size of Medicaid expansion enrollment and attrition sources - The Medicaid expansion population is approximately 1.3 million members, with expected attrition of 15%-20% due to new work requirements [59][60] Question: Positive and negative dynamics affecting 2026 guidance - Management believes there are no significant negative dynamics, with a focus on potential upside from rate adjustments and cost trends [62][64]